I can email him. He retired on the 15th of December but maybe he can answer the question.
Pity that he retired, but in regards to the email I guess you could send him the following (although I wish I knew how much to write, hopefully this isn't TL;DR, feel free to just ask him about the Pimavanserin as I have no idea how open to communication he is and if he is still passionate about his brainchild HPPD)
"Hello doctor, I was hoping to hear from you about Pimavanserin and if it may have use in treating HPPD.
Do you think that changes to parvalbumin positive GABA interneurons like decreased expression of PV (caused by glutamate release via 5-HT2A activation in the case of MDMA) can cause HPPD and other issues (rather than excitotoxic destruction of said interneurons), and then the changes in PV/GAD67 expression could reverse to some degree with chronic 5-HT2A blockade?
Even if 5-HT2A blockade leads to a temporary decrease in the activity of PV GABA interneurons and a surge in symptoms, I wonder if the possible changes associated with 5-HT2A over-activation are bi-directional, and hence I'm curious if Pimavanserin holds any promise for treating HPPD.
The various case reports of HPPD seem difficult to piece together. There are reports of initial exacerbation of HPPD when starting treatment with AAPs and SSRIs, but then there is a gradual decrease in symptoms.
I'm wondering in particular if Pimavanserin may hold any promise as opposed to a silent/neutral antagonist like Trazodone that may allow the receptors to build up (even though regulation of 5-HT2A is atypical in regards to chronic blockade causing desensitization) and then the constitutive activity of 5-HT2A may wreak havoc, as appears to be the case with Parkinson's disease psychosis due to 5-HT2A supersensitivity.
MDMA users show upregulation of 5-HT2A in visual cortex among other regions, so I wonder if there isn't already an element of some excess constitutive activity (if only at particular synapses) that wouldn't be stopped by a neutral antagonist. Unfortunately it seems that the orthosteric site binding antagonists like Risperidone are going to have the issue of dopaminergic blockade, and seeing as COMT inhibitors are helpful to some HPPD patients that could be expected to worsen symptoms/cause side effects in the meantime while waiting for desensitization of 5-HT2A with chronic blockade.
I'm told it is the case with ketamine that parvalbumin positive neurons are still there but no longer expressing parvalbumin. Recent studies have shown there is a decrease in GAD67 and PV immunoreactivity after MDMA administration in animals.
If the PV neurons have undergone such changes like decreased expression of GAD67/PV after excess 5-HT2A activation and this is relevant a cause of symptoms, how may we go about reversing these changes? There seems to be evidence that HDAC inhibitors and clozapine may help with PV interneuron issues in schizophrenia.
Many thanks for any thoughts."
Something like that... Too long? I'm thinking about posting this possible email over in Neuroscience in Pharmacology and seeing if I can get any critique. In addition I might try to email some university staff, some have been open to communication in the past.